CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop a platform for discovering new drugs targeting protein kinases, which are crucial for many cellular processes and diseases. It combines advanced technologies and academic expertise to create inhibitors that could lead to innovative cancer treatments.
Protein kinases are involved in the control of a large number of cellular processes and play a central role in human physiology.
More than 500 genes encoding protein kinases have been identified in the human genome, and it is estimated that about 30% of all human proteins may be phosphorylated by kinases.
Deficiency in kinase activity has implications in cancer, central nervous system disorders, autoimmune diseases and immunosuppression, diabetes, osteoporosis and various metabolic disorders.
Sm…
SAROMICS BIOSTRUCTURES AB
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
France, ILLKIRCH-GRAFFENSTADEN
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Germany, FREIBURG
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Italy, Torino
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
